https://pubmed.ncbi.nlm.nih.gov/18286536/
The gemcitabine and vinorelbine combination was moderately active and had an acceptable toxicity profile in pemetrexed-pretreated patients with MPM. The role...
gemcitabinevinorelbinepemetrexedpatientsmalignant
https://pubmed.ncbi.nlm.nih.gov/19841321/
The study did not meet its primary end point. However, the median PFS time of 4 months is promising. Pharmacogenetic studies in larger cohorts are needed to...
phase ii trialsecond linepemetrexedplusbevacizumab
https://pubmed.ncbi.nlm.nih.gov/31687290/
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death. The American Society for Clinical Oncology (ASCO) recommends platinum based...
pemetrexedinducedlifethreateninganaphylaxis